THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Business in brief

No new brain infections linked to use of Tysabri

April 16, 2008

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Biogen Idec Inc., the world's largest maker of multiple sclerosis drugs, said its fastest- growing product, Tysabri, was linked to no new cases of the deadly brain infection tied to the drug three years ago. The drug was being taken by 26,000 patients worldwide as of March 31, the Cambridge company said. Biogen and its partner, Irish drug maker Elan ... (Full article: 698 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass